GEN Exclusives

More »

GEN News Highlights

More »
Jul 20, 2007

Santarus Receives $5M Milestone Fee from Schering-Plough

  • Santarus achieved a $5-million milestone in its license agreement with Schering-Plough HealthCare Products for its proton pump inhibitor (PPI).

    The over-the-counter (OTC) license agreement gives Schering-Plough the right to develop, manufacture, and commercialize OTC products using Santarus' PPI technology with the lower-dosage strength of 20 mg of omeprazole for heartburn-related indications in the U.S. and Canada. Santarus will continue to manufacture and sell its Zegerid prescription products in both 20-mg and 40-mg dosage strengths in the U.S.

    In addition to the $15 million Santarus received upfront and this milestone fee, the company could receive up to $60 million in milestone payments plus low double-digit royalties. In turn, Santarus will be obligated to pay royalties to the University of Missouri on net sales of any such OTC products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?